Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma

被引：43
|
作者：
Mehta, Anurag [1 ]
Gupta, Arjun [1 ]
Hannallah, Franck [1 ]
Koshy, Thomas [2 ]
Reimold, Sharon [2 ]
机构：
[1] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA
[2] Univ Texas SW Med Ctr Dallas, Dept Cardiol, Dallas, TX 75390 USA
来源：
MELANOMA RESEARCH | 2016年 / 26卷 / 03期
关键词：
D O I：
10.1097/CMR.0000000000000251
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：319 / 320
页数：2
相关论文
共 50 条
  • [1] Correlation between immune-related adverse events and outcomes in nivolumab/ipilimumab combination therapy for metastatic melanoma
    Rauwerdink, Daan
    Frederick, Dennie T.
    Sharova, Tatyana
    Marie, Genevieve
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
  • [2] Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report
    Miyauchi, Yasuyuki
    Naito, Hirohito
    Tsunemori, Hiroyuki
    Tani, Ryosuke
    Hasui, Yusuke
    Miyake, Yuichi
    Minamino, Tetsuo
    Ishikawa, Ryo
    Kushida, Yoshio
    Haba, Reiji
    Sugimoto, Mikio
    JOURNAL OF MEDICAL CASE REPORTS, 2021, 15 (01)
  • [3] Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report
    Yasuyuki Miyauchi
    Hirohito Naito
    Hiroyuki Tsunemori
    Ryosuke Tani
    Yusuke Hasui
    Yuichi Miyake
    Tetsuo Minamino
    Ryo Ishikawa
    Yoshio Kushida
    Reiji Haba
    Mikio Sugimoto
    Journal of Medical Case Reports, 15
  • [4] Efficacy and immune-related adverse events of ipilimumab and nivolumab combination therapy for a vaginal malignant melanoma
    Mitsutake, Yano
    Kota, Konishi
    Mamiko, Okamoto
    Kaei, Nasu
    JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2022, 153
  • [5] Ipilimumab and nivolumab induced immune-related adverse events in metastatic mucosal melanoma
    Cao, Yenong
    Afzal, Muhammad Zubair
    Shirai, Keisuke
    BMJ CASE REPORTS, 2021, 14 (08)
  • [6] A CASE OF A NEUROLOGICAL IMMUNE-RELATED ADVERSE EVENT ASSOCIATED WITH IPILIMUMAB/NIVOLUMAB
    Walker, Josh
    Farag, Mena
    Josephs, Debra
    Williams, Victoria
    Holmes, Paul
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (09):
  • [7] A case of dual-mechanism hematologic immune-related adverse event in a patient with metastatic melanoma treated with combined nivolumab and ipilimumab
    Olson, Daniel
    Tjota, Melissa
    Rajagopal, Padma
    Venkataraman, Girish
    Luke, Jason
    Gajewski, Thomas
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [8] Immune-related pancytopenia caused by nivolumab and ipilimumab combination therapy for unresectable melanoma of unknown primary
    Uehara, Jiro
    Yoshino, Koji
    Sugiyama, Eiki
    Ohkuma, Kaori
    Oaku, Satoe
    Yamashita, Chisato
    Hiura, Azusa
    Fujisawa, Yasuhiro
    JOURNAL OF DERMATOLOGY, 2020, 47 (06): : E237 - E239
  • [9] Role of nivolumab maintenance therapy in advanced melanoma patients following severe immune-related adverse events from combination nivolumab and ipilimumab.
    Maloney, Anna
    Giobbie-Hurder, Anita
    Fogarasi, Miklos C.
    Ott, Patrick Alexander
    Hodi, F. Stephen
    Sussman, Tamara A.
    Silk, Ann W.
    Haq, Rizwan
    Liu, David
    Insco, Megan Leigh
    Buchbinder, Elizabeth Iannotti
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Immune-Related Esophagitis and Duodenitis Secondary to Nivolumab-Ipilimumab Combination Therapy
    Wang, Susan
    Morales, Shannon
    Ren, Bing
    Drinane, Mary
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S1031 - S1032
12345